Randomized clinical trial of topical betaxolol for peritent macular edema after vitrectomy and epiretinal membrane removal

Purpoe To report the efficacy and afety of topical betaxolol for treatment of peritent macular edema. Deign Randomized clinical trial. Method Thirty-even eye (37 patient) with bet-corrected viual acuity between 20/200 and 20/50 and macular edema that remained for 3 month after vitrectomy and removal of epiretinal membrane were propectively, randomly aigned to receive betaxolol or placebo. Nineteen eye of 19 patient received betaxolol twice daily, and 18 eye of 18 patient received placebo a a randomized comparion group. The patient were followed up for 6 month. Thi tudy evaluated the effect of betaxolol on bet-corrected viual acuity and area of macular edema, which wa digitally meaured on erial fluorecein angiogram. Calculation of mean bet-corrected viual acuity were baed on logarithm of the minimal angle of reolution (logMAR). To ae change in area of edema, the initial (pretreatment) ize of the edema wa et to 100%, and all pottreatment meaurement were normalized relative to the initial ize. Reult Mean bet-corrected viual acuity at baeline wa 0.216 (20 of 92.6) and 0.244 (20 of 82.0) in the treatment and control group, repectively. Mean area of macular edema wa 2.271 ± 1.629 mm2 and 2.273 ± 1.209 mm2 in the treatment and control group; there wa no ignificant difference. The viual acuity at 6 month after the tart of the follow-up wa 0.471 (20 of 42.5) in the treatment group and 0.236 (20 of 84.7) in the control group. Mean change in logMAR of viual acuity for 3- and 6-month follow-up were −0.282 ± 0.191 and −0.337 ± 0.197 in the treatment group, and −0.016 ± 0.186 and +0.015 ± 0.267 in the control group; a ignificant difference wa found (P <.0001; P <.0001). Area of macular edema at 6 month after the tart of the follow-up were 1.492 ± 1.357 mm2 in the treatment group and 2.125 ± 1.434 mm2in the control group. Mean change in area of the edema for 6 month were 76.5% ± 24.1% and 63.4% ± 28.3% in the treatment group and 92.9% ± 15.4% and 87.4% ± 25.6% in the control group; treated patient howed a ignificantly larger reduction than untreated patient at each examination (P = .0193; P = .0102). No complication aociated with treatment or placebo wa found. Concluion Topical betaxolol appeared to have a favorable treatment effect in eye with macular edema that remained after vitrectomy and removal of epiretinal membrane. Further invetigation of more cae and longer follow-up are needed.